The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

The need to change regulations around gene-editing treatments was endorsed in November by the head of the US Food and Drug ...

A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...

Thanks to genetic science, gene editing, and techniques like cloning, it’s now possible to move DNA through time, studying ...

Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of ...

Advanced biotechnology repurposes two bacterial immune systems to correct large stretches of DNA. Human cells that have been edited with the new retron-based gene editing technology. Orange dots mark ...

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ) ...

Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting ...